MPN-545 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide as Second Line Therapy in Essential Thrombocythemia
Journal
Clinical lymphoma, myeloma & leukemia
Journal Volume
22 Suppl 2
Pages
S342
Date Issued
2022-10
Author(s)
Mesa, Ruben
Komatsu, Norio
Gill, Harinder
Jin, Jie
Lee, Sung-Eun
Sato, Toshiaki
Qin, Albert
Urbanski, Raymond
Shih, Weichung
Zagrijtschuk, Oleh
Zimmerman, Craig
Verstovsek, Srdan
Abstract
Low-dose aspirin with hydroxyurea (HU) is first-line therapy in high-risk essential thrombocythemia (ET). However, many patients become HU-intolerant or -resistant. Anagrelide (ANA) and peginterferon alfa-2a are second-line options for high-risk ET patients.
Subjects
MPN; P1101; Trial-in-Progress; anagrelide; essential thrombocythemia; myeloproliferative neoplasm; ropeginterferon alfa-2b-njft
Type
journal article